EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial

Cazzaniga Marina Elena, Pepe Francesca Fulvia, Rossi Emanuela, Coltelli Luigi, Beano Alessandra, Valerio Maria Rosaria, Ferro Antonella, Zustovich Fable, Moretti Gabriella, Toniolo Davide, Cordani Nicoletta, Galimberti Stefania und 1 weitere

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2025.05.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Cazzaniga Marina Elena und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy; Phase 1 Research Centre, Fondazione IRCCS San Gerardo dei Tintori, Mo…. Hauptthemen laut MEDLINE: Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Benzimidazoles. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Università degli Studi di Milano-Bicocca, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: CDK 4/6 inhibitors with ET are the recommended choice as 1st-line therapy in HR+/HER2- MBC patients, however ET alone could remain an option for some of them. HERMIONE-7 is a multicenter, single-arm, Phase II study, aimed to evaluate Abemaciclib 150 mg BID + AIs, in patients who progressed on 1st line Fulvestrant. MATERIALS AND METHODS: Primary aim was the efficacy of Abemaciclib + AIs in terms of Clinical Benefit Rate (CBR), secondary aims were Time to Progression (TTP), Overall Response Rate (ORR), duration of response (DOR), and safety. RESULTS: From April 2020 to January 2022, we enrolled 31 patients. Median age was 72 years (range 47-86), 55% had < 2 comorbidities, mainly hypertension (12, 38.7%). Clinical Benefit Rate was 69% (95% CI, 49-85) and ORR was 21% (95%CI, 8-40). 1-year TTP and OS rates were 53.8% (95% CI, 38.6-74.9%) and 69.5% (95% CI, 54.8%-88.5%), respectively. Main adverse events remain diarrhea (80.6%), fatigue (54.8%) and nausea (35.5%), 3 patients (10.7%) had non drug-related fatal events. CONCLUSIONS: HERMIONE-7 study showed that 2nd-line treatment with Abemaciclib + AIs is a feasible option in MBC patients who progressed on Fulvestrant in 1st-line setting and could be an alternative especially in terms of optimizing the cost-benefit ratio in some Countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBenzimidazolesBreast NeoplasmsAgedAged, 80 and overFemaleHumansMiddle AgedFulvestrantErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Stichwörter der Autor:innen

AbemaciclibBreast cancerFulvestrantHR+/HER2-Second-line

Substanzen

AminopyridinesAromatase InhibitorsBenzimidazolesFulvestrantErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneabemaciclibERBB2 protein, human

Autor:innen und Institutionen

  • School of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy; Phase 1 Research Centre, Fondazione IRCCS San Gerardo dei Tintori, Monza, MB, Italy. Electronic address: Marina.cazzaniga@unimib.it.
  • Phase 1 Research Centre, Fondazione IRCCS San Gerardo dei Tintori, Monza, MB, Italy.
  • School of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy.
  • Struttura Complessa di Oncologia Medica AVC-VDE, Ospedale Felice Lotti Pontedera e Ospedale Santa Maria Maddalena Volterra, Pisa, Italy.
  • SSD Oncologia Senologica, Dipartimento di Oncologia, AOU CIttà della Salute e della Scienza C. Torino, Italy.
  • Department of Precision Medicine in Medical, Surgical and Critical Area (MePreCC) University of Palermo, Palermo, Italy.

Förderung

  • Università degli Studi di Milano-Bicocca
  • Eli Lilly and Company

Zitieren

APA

Elena, C. M., Fulvia, P. F., Emanuela, R., Luigi, C., Alessandra, B., Rosaria, V. M., Antonella, F., Fable, Z., Gabriella, M., Davide, T., Nicoletta, C., Stefania, G., & Serena, C. (2025). A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.05.003

Vancouver

Elena CM, Fulvia PF, Emanuela R, Luigi C, Alessandra B, Rosaria VM, et al. A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.05.003

BibTeX
@article{Elena2025,
  author = {Elena, Cazzaniga Marina and Fulvia, Pepe Francesca and Emanuela, Rossi and Luigi, Coltelli and Alessandra, Beano and Rosaria, Valerio Maria and Antonella, Ferro and Fable, Zustovich and Gabriella, Moretti and Davide, Toniolo and Nicoletta, Cordani and Stefania, Galimberti and Serena, Capici},
  title = {A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2025.05.003}
}
Kostenlos starten →